AbstrAct -Background: Individualized use of glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in scenarios with high thrombotic load or occurrence of coronary flow abnormalities may be considered, despite scarce scientific evidence. Our objective was to compare patients undergoing primary percutaneous coronary intervention treated or not with glycoprotein IIb/IIIa inhibitors during the procedure. Methods: A national, multicenter, retrospective study that included consecutive patients undergoing primary percutaneous coronary intervention, treated or not with glycoprotein IIb/IIIa inhibitors, between June 2006 and March 2016, using the database of the Central Nacional de Intervenções Cardiovasculares (CENIC). Results: We enrolled 18,690 patients, of which 3,032 (16.2%) received glycoprotein IIb/IIIa inhibitors. The mean age was 61.5±12.4 years, 69.5% were men, and 19.9% had diabetes mellitus. The group receiving glycoprotein IIb/IIIa inhibitors had a higher prevalence of long, thrombotic, bifurcation lesions, occlusions or TIMI flow grade <2. This group showed higher mortality (3.7% vs. 4.8%; p=0.0046), reinfarction (0.5% vs. 1.1%; p<0.0001) and major adverse cardiac event rates (4.0% vs. 5.7%; p<0.0001). In the univariate analysis, the use of glycoprotein IIb/IIIa inhibitors was associated with a higher chance of death (RR 1.31; 95%CI 1.09-1.58; p=0.0048), but was not confirmed as an independent predictor in the multivariate analysis. Conclusion: Among patients undergoing primary percutaneous coronary intervention, the group treated with glycoprotein IIb/IIIa inhibitors had greater clinical severity and anatomical complexity, and worse in-hospital clinical outcomes.
independente na análise multivariada. Conclusão: Entre pacientes submetidos à intervenção coronária percutânea primária, o uso de inibidores da glicoproteína IIb/IIIa caracteriza um grupo de maior gravidade clínica, complexidade anatômica e pior evolução hospitalar.
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INtrodUctIoN
Adjunctive platelet glycoprotein (GP) IIb/IIIa inhibitors in acute coronary syndrome (ACS) aims to reduce thrombus load and restore coronary perfusion. Despite appropriate reestablishment of coronary flow after primary percutaneous coronary intervention (PCI), distal embolization of atherothrombotic debris may negatively impact the microcirculation, which represents a relevant application of these drugs with high antiplatelet action. [1] [2] [3] [4] Before the advent of the dual antiplatelet therapy currently in use, studies like EPIC (Evaluation of 7E3 for the Prevention of Ischemic Complications), EPILOG (Evaluation in PTCA to Improve Long-Term Outcome with Abciximab GP IIb/IIIa Blockade) and EPISTENT (Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial) showed a combined reduction in major adverse cardiac events (MACE) and boosted the use of GP IIb/IIIa inhibitors in ACS. [5] [6] [7] [8] In Brazil, only tirofiban and abciximab are commercially available. 9 In combination with current antithrombotic therapies, routine use of GP IIb/IIIa inhibitors is not beneficial, and can lead to higher rates of severe bleeding. 10 Individualized use may be considered in specific situations, such as high thrombotic load, slow/no reflow phenomenon, coronary dissections, or other thrombotic complications. 11, 12 This study aimed to compare the profile and in-hospital outcomes of patients subjected to primary PCI, trea ted or not with adjunctive GP IIb/IIIa inhibitors, in addition to verifying the influence of variables of interest on mortality.
MetHods
A national, multicenter, retrospective study of all consecutive patients subjected to primary PCI, between June 2006 and March 2016, comparing patients treated or not with GP IIb/IIIa inhibitors during the pro cedure. Data were collected from the database of the Central Nacional de Intervenções Cardiovasculares (CENIC; http://www.corehemo.net/).
Patients were characterized by clinical, angiographic, procedure-related and MACE criteria during the hospital phase, including the occurrence of death, non-fatal infarction or urgent coronary artery bypass surgery (CABG). This study follows the recommendations of the Declaration of Helsinki and Resolution 466/12 of the National Health Council and has been approved by the local ethics committee under protocol 2.992.506 (CAAE: 01989218.2.0000.5485).
statistical analysis
Descriptive statistics were presented for clinical, angiographic and procedure-related characteristics, in-hospital clinical outcomes, and procedural success in patients eligible for the analysis. For continuous variables, mean and standard deviation was presented and, for categorical variables, contingency tables were presented with absolute and percentage frequencies.
Comparative analysis of categorical variables was performed using the Chi-square test and, when necessary, the likelihood ratio. Continuous variables were compared using the Student's t test. For multiple comparisons, we used the Bonferroni correction.
To assess the influence of variables of interest on mortality, the simple logistic regression model was used. The independent variables in the univariate regression model were tested with the forward selection method and included in the multivariate analysis. Variables with high loss of information (e.g. ventricular dysfunction and collateral circulation) were disregarded in the multiple analysis. For all analyses, the level of significance was set as p<0.05.
resULts
A total of 18,690 patients were analyzed, with mean age of 61.5±12.4 years, of which 69.5% were men, and 19.9% had diabetes mellitus. The clinical characteristics are listed in Table 1 Regarding in-hospital clinical outcomes, mortality was higher (4.8% vs. 3.7%; p=0.0046) in the group treated with GP IIb/IIIa inhibitors, as well as the incidence of MACE (5.7% vs. 4.0%; p<0.0001) and reinfarction (1.1% vs. 0.5%; p<0.0001) ( Table 4 ). In the univariate analysis, Results expressed as mean ± standard deviation or n (%). MI: myocardial infarction; PCI: percutaneous coronary intervention; CABG: coronary artery bypass surgery. Results expressed as n (%). CABG: coronary artery bypass surgery; MACE: major adverse cardiac events.
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the use of GP IIb/IIIa inhibitors was associated with a greater chance of death (RR 1.31; 95%CI: 1.09-1.58; p=0.0048), but it was not confirmed as an independent predictor in the multivariate analysis. In the latter, the variables that best correlated with mortality were age, female gender, hypertension, dyslipidemia, diabetes mellitus, prior infarction, Killip class, and extent of the coronary artery disease (Table 5 ).
